A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from *Anemarrhena asphodeloides* Bge for Treating Alzheimer’s Disease

Yu Sun,1 Ying Peng,2 Lin-Guang Li,1 Li-Wei Zheng,2 Dong-Ju Lin,2 Ling-Zhi Li,1,3 and Shao-Jiang Song1,3

1 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China
2 School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China
3 Key Laboratory of Structure-Based, Drug Design & Discovery, Ministry of Education, Shenyang, Liaoning 110016, China

Correspondence should be addressed to Shao-Jiang Song; songsj99@163.com

Received 4 November 2013; Revised 2 March 2014; Accepted 20 March 2014; Published 17 April 2014

Academic Editor: Chuthamanee Suthisisang

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss and cognitive impairment. Cholinesterase inhibitors are widely used for the symptomatic treatment of Alzheimer’s disease to enhance central cholinergic transmission. In this study, a bioactivity-oriented screening platform based on a modified Ellman’s method and HPLC-QTOFMS technique was developed to rapidly screen active agents of *Anemarrhena asphodeloides* Bge. The 60% ethanol fraction from an ethyl acetate extract exhibited the most potential anticholinesterase activity. Fifteen steroid saponins were identified by the mass spectrum, standards and literature reports. Twenty-five compounds were isolated from the active fraction. The results showed that compounds with the C$_6$–C$_3$–C$_6$ skeleton probably had both AChE and BuChE inhibitory activities. Xanthone and benzene derivatives exhibited no or little activity. Lignans showed weak BuChE inhibitory activity. The steroidal saponins demonstrated moderate or weak AChE inhibitory activity.

1. Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS), characterized by deposits of aberrant proteins, namely, β-amyloid (Aβ) and τ-protein, loss of synapses, death of cholinergic neurons, and oxidative stress [1, 2]. The etiopathogenesis of AD still remains unknown, although the neurodegeneration leads to remarkable reduction of neurotransmitter acetylcholine at the synaptic clefts [3, 4]. An effective strategy to slow down the progression of deterioration in AD patients is using anticholinesterase inhibitors.

Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) constitute the group of cholinesterases. AChE hydrolyses acetylcholine (ACh) and is mainly associated with nerves and muscles, being typically found on the synapses. AChE inhibitors are widely used for the symptomatic treatment of AD to enhance central cholinergic transmission. BuChE hydrolyses butyrylcholine (BuCh) and is synthesized by the liver, being found in large concentration in serum [5]. In healthy brains, AChE hydrolyzes the majority of ACh while BuChE plays a secondary role. However, as AD progresses, BuChE can compensate for AChE when the activity of AChE is inhibited by AChE inhibitors. Thus, BuChE hydrolyses the already depleted levels of ACh in these patients [6]. It has been proposed that individuals with low activity of BuChE can sustain cognitive functions better than individuals with normal BuChE activity. Furthermore, BuChE inhibitors have been reported to produce a significant increase in brain extracellular AChE without triggering severe peripheral or central side effects [7].

*Anemarrhena asphodeloides* Bge, which belongs to the family Liliaceae, is widely distributed in China [8]. The rhizomes of *Anemarrhena asphodeloides* Bge have been reported
to have the cholinesterase inhibitory activity relevant to treatment of AD [9]. In order to find the candidate of a drug treating AD, the activities of fractions and compounds were assayed. Screening and identification of bioactive constituents in traditional Chinese medicines (TCMs) are the keys of the development of TCMs [10, 11]. However, the complexity and variability of TCMs present a challenge to the identification of their structures. Now more and more attention has been attracted to bioactivity-based LC-MS/MS identification technology owing to its high efficiency and high specificity [12, 13].

In this work, we used a bioactivity-oriented screening strategy, which was based on a modified Ellman’s method and high performance liquid chromatography quadrupole-time-of-flight mass spectrometer (HPLC-QTOF MS) technique. The 60% ethanol fraction from an ethyl acetate extract showed the most potential anticholinesterase activity. Fifteen steroid saponins were identified by the mass spectrum, standards, and literature reports. Twenty-five compounds were isolated from the active fraction. Compounds with the C25-C3-C17 skeleton probably had both AChE and BuChE inhibitory activities. Xanthone and benzene derivatives exhibited no or little activity. Lignans showed weak BuChE inhibitory activity. The steroid saponins demonstrated moderate or weak AChE inhibitory activity.

2. Materials and Methods

2.1. Plant Material. The rhizomes of Anemarrhena asphodeloides Bge were purchased from Beijing Tongrentang pharmacy. The plant materials were identified by Professor Jincai Lu, Department of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University.

2.2. General Instrumental Equipment. HPLC system (Agilent, USA) consisted of a model G1276A pump, model G1367B Autosampler and model G1316A UV detector. The chromatograph was equipped with a reversed-phase C18 column of Grace Alltima (250 mm × 4.6 mm, 5 μm). The QTOF-MS system (Bruker, Germany) with an ESI source was performed. HPLC separations were performed on a Hitachi 655–15 series pumping system equipped with a Hitachi L-2490 refractive index detector using a YMC-Park ODS-A column (250 × 10 mm I.D, S-5 μm, and 12 nm). NMR spectra were performed on a Bruker ARX-300, ARX-400, and ARX-600 spectrometer using trimethylchlorosilane as the internal standard. Column chromatography was performed on a 200–300 mesh silica gel (Qingdao Marine Chemical Factory, People’s Republic of China). Column chromatography was performed using YMC ODS-A gel (12 mm S-75 μm, YMC Co., Ltd., Japan) and D-101 macroporous adsorption resin (Shanghai Hualing Resin Factory, People’s Republic of China). TLC was performed with precoated silica gel GF254 plates (Qingdao Marine Chemical Factory, People’s Republic of China). Microplate reader (Thermofisher Scientific, Finland) was used to test the activities. Acetylthiocholine iodide, S-butryrylthiocholine iodide, AChE, and BuChE were bought from Sigma Company.

2.3. Extraction Procedures. Dried rhizomes of Anemarrhena asphodeloides Bge were powdered into a homogeneous size by a disintegrator and then sieved (60 mesh). The materials were extracted by three different techniques (ultrasonic, heat reflux, and cold soak techniques). Various solvents including petroleum ether, dichloromethane, ethyl acetate, acetone, methanol, 95% ethanol, 70% ethanol, 50% ethanol, 30% ethanol, and water were used for preparing active fractions. Accurate 5.0 g of the Anemarrhena asphodeloides Bge powders was weighed into ten Erlenmeyer flasks containing the mentioned ten solvents of 500 mL individually and then extracted with ultrasonic-assisted method twice (30 min each). After filtering, the filtrates were amalgamated and evaporated to dryness by rotary evaporator (50 °C). For the heat reflux, the powders of 5.0 g were soaked in different solvents of 50 mL each for 30 min. Then, the heated reflux extraction experiments were conducted in water bath (90 °C) for 2 h. The solutions were filtrated when they were still hot. Extractions were carried out for three times and the filtrates were evaporated to dryness. Lastly, 5.0 g of the powders was accurately weighed and soaked in 500 mL solvents overnight and then evaporated the filtrates to dryness.

2.4. AChE and BuChE Inhibitory Assay. Cholinesterase inhibitory activity was evaluated using the modified method of Ellman. For AChE inhibitory assay, the reaction mixture consisted of 50 μL of 100 mM PBS, pH 8.0, 25 μL of 15 mM acetylthiocholine iodide, and 25 μL of agents (1 mg/mL for extracts, 0.1 mg/mL for compounds) in a 96-well plate. The mixture was preincubated in 4 °C for 10 min, and after that, 25 μL of AChE (0.226 U/mL) and 125 μL of 3 mM DTNB were added. The reactions were kept in 37 °C for 20 min and then scanned at 412 nm with a microplate reader. For BuChE inhibitory assay, the same procedures were followed except for the use of substrate and enzyme, and S-butyrylthiocholine iodide and BuchE were used, respectively [14]. All of the experiments were repeated at least three times.

2.5. Structure Characterization and Identification of Active Fraction. The ethyl acetate extract dealt with by the ultrasonic method was applied to a D-101macroporous resin column and eluted with ethanol and water to give 0%, 20%, 40%, 60%, 80%, and 95% ethanol fractions. The constituents of active fraction were assayed by HPLC-QTOF-MS. HPLC system (Agilent, USA) consisted of a model G1276A pump, a model G1367B Autosampler, and a model G1316A UV detector. The chromatograph was equipped with a reversed-phase C18 column of Grace Alltima (250 mm × 4.6 mm, 5 μm) eluted with a gradient mobile phase. Mobile phases were water with 0.1% of formic acid (A) and acetonitrile (B). The gradient used was as follows: 0 min, 5% B; 0–10 min, 5% to 15% B; 10–18 min, 15% to 20% B; 18–23 min, 20% to 23% B; 23–30 min, 23% to 25% B; 30–48 min, 25% to 30% B; 48–55 min, 30% to 50% B; 55–80 min, 50% to 100% B. The injection volume of sample was 5 μL. The flow rate was 0.8 mL min⁻¹ and the column temperature was ambient temperature. The QTOF-MS system (Bruker, Germany) with an ESI source was performed in positive mode. The parameters of ESI-MS were
Evidence-Based Complementary and Alternative Medicine

The extract of *Anemarrhena asphodeloides* Bge

D-101 macroporous resin column

A B C D E F

Silica gel

D.1 D.2 D.3 D.4 D.5

Reversed-phase C18 silica gel

D.2.1 D.2.2 D.2.3

HPLC

Components 13–15 Components 1–7

Sephadex LH-20 Pre-HPLC

D.4.1 D.4.2 D.4.3 D.4.4

Sephadex LH-20 Pre-HPLC

Silica gel Pre-HPLC

Components 8–12 Components 16–25

Figure 1: The isolation procedure of *Anemarrhena asphodeloides* Bge.

2.6. Isolation and Purification of Compounds from *Anemarrhena asphodeloides* Bge. The extract of *Anemarrhena asphodeloides* Bge (400.0 g) was subjected to CC (macroporous adsorption resin D-101; gradient EtOH/H2O 0:100 to 95:5) to afford six fractions (Frs. A–F). Fr. D (62.0 g) was subjected to CC (silica gel; CH2Cl2/MeOH 100:0 to 0:100) and afforded five fractions (Frs. D.1–D.5). Fr. D.2 (5.2 g) was subjected to CC (reversed-phase C18 silica gel; MeOH/H2O 30:70 to 100:0) to afford three fractions (Frs. D.2.1–D.2.3). Fr. D.2.2 (0.7 g) was further purified by RP-HPLC with MeOH/H2O as mobile phase (85:15) to afford compounds 13 to 15. Fr. D.3 (2.3 g) was subjected to CC (Sephadex LH-20; MeOH) and then purified by RP-HPLC with MeOH/H2O as mobile phase (80:10) to afford compounds 1 to 7. Fr. D.4 (21.0 g) was subjected to CC (reversed-phase C18 silica gel; MeOH/H2O 30:70 to 100:0) and afforded four fractions. Fr. D.4.2 (3.3 g) was subjected to CC (Sephadex LH-20; MeOH) and then purified by RP-HPLC with MeOH/H2O as mobile phase (50:50) to afford compounds 8 to 12. Fr. D.4.4 (9.7 g) was subjected to CC (silica gel; CH2Cl2/MeOH 30:70 to 100:0) and then purified by RP-HPLC with MeOH/H2O as mobile phase (70:30) to afford compounds 16 to 25. The isolation procedure of *Anemarrhena asphodeloides* Bge is shown in Figure 1.

2.7. Statistical Analysis. Data were expressed as means ± S8EM and analyzed statistically by one-way ANOVA, followed by post hoc (LSD) test. The results were considered statistically significant at \( P \) value < 0.05.

3. Results

3.1. The Activities of the Extracts. Screening the extracts of *Anemarrhena asphodeloides* Bge dealing with three different techniques and ten kinds of solvents showed that all the extracts demonstrated no AchE inhibitory activity but exhibited BuChE inhibitory activity. The extract dealing with dichloromethane, ethyl acetate, and acetone had much more inhibition ratio than the others. The ultrasonic method and the cold soak method were better than the heat reflux method. It was found that *Anemarrhena asphodeloides* Bge extracted with ethyl acetate by the ultrasonic technique had the most potential anticholinesterase activity. The results on the effects of the tested extracts on AChE and BuChE inhibitory activities were summarized in Table 1.

3.2. Screening the Active Fraction. The extract dealing with ethyl acetate by the ultrasonic method was applied to a D-101 macroporous resin column and eluted with ethanol and water to give 0%, 20%, 40%, 60%, 80%, and 95% ethanol fractions. Then they were tested on AChE and BuChE inhibitory activities. It indicated that the extract was partitioned into six fractions and active compounds were concentrated into 60% ethanol fraction. The results were summarized in Figure 2. Donepezil was used as positive drug with the inhibition ratio of 98.2% and 79.8%.

set as follows: the capillary voltage (+3800 V), the nebulizer gas pressure (1.2 bar), the dry gas flow rate (8.0 L min\(^{-1}\)), and temperature (180°C). MS conditions were corrected by direct infusion of sodium formic acid solution (1 mM L\(^{-1}\)) delivered by a syringe pump at a flow rate of 3 \(\mu\)L min\(^{-1}\). The data were analyzed by Bruker Daltonics Data Analysis 3.4 software.
Table 1: The effects of the tested extracts on AChE and BuChE inhibitory activities.

| Solvents          | AChE inhibition (%) | BuChE inhibition (%) |
|-------------------|---------------------|----------------------|
|                   | Ultrasonic method   | Heat reflux method   | Cold soak method | Ultrasonic method | Heat reflux method | Cold soak method |
| Petroleum ether   | —                   | —                    | —                | —                | —                   | 1.6 ± 0.1        |
| Dichloromethane   | —                   | —                    | —                | 41.5 ± 0.5       | 15.7 ± 0.7          | 41.2 ± 0.6       |
| Ethyl acetate     | —                   | —                    | —                | 44.1 ± 0.5       | 27.7 ± 0.4          | 40.8 ± 0.8       |
| Acetone           | —                   | —                    | —                | 38.8 ± 0.3       | 22.2 ± 0.3          | 37.9 ± 0.7       |
| Methanol          | —                   | —                    | —                | 12.3 ± 0.4       | 5.4 ± 0.2           | 7.1 ± 0.3        |
| 95% ethanol       | —                   | —                    | —                | 4.9 ± 0.2        | 2.8 ± 0.1           | 3.9 ± 0.3        |
| 70% ethanol       | —                   | —                    | —                | 1.8 ± 0.1        | —                   | 1.6 ± 0.2        |
| 50% ethanol       | —                   | —                    | —                | 2.8 ± 0.1        | —                   | 0.5 ± 0.1        |
| 30% ethanol       | —                   | —                    | —                | 2.4 ± 0.1        | —                   | 1.8 ± 0.2        |
| Water             | —                   | —                    | —                | —                | —                   | —                |

AChE inhibition ratio of donepezil: 98.0 ± 0.5; BuChE inhibition ratio of donepezil: 80.2 ± 0.6.

Figure 2: The effects of ethanol and water fractions on AChE and BuChE inhibitory activities.

3.3. Structure Characterization and Identification of the Active Fraction. The 20%, 40%, 60%, 80%, and 95% ethanol fractions were analyzed by HPLC-QTOF-MS technique. The water fraction was not tested for its inactivity. The total ion chromatograms of the five fractions were shown in Figure 3. As summarized in Table 2, a total of fifteen saponins from the 60% ethanol fraction were identified and tentatively characterized.

To obtain the information about precursor ions and characteristic fragment ions of the compounds, six authentic standards were injected into the LC-MS system. The fragmentation patterns for these authentic standards were discussed in detail below. MS spectra of the authentic standards were shown in Figure 4.

Timosaponin BII produced a precursor ion [M + Na]⁺ at m/z 943.4872 (C_{45}H_{76}O_{19}Na). As the C22 position was an active site, it readily eliminated the 22-hydroxyl residue to produce the thermal degradation ion [M + H – H₂O]⁺ at m/z 903.4982 (C_{45}H_{75}O_{18}), which could generate an ion at m/z 741.4468 [M + H – H₂O – 162]⁺ by further neutral loss of a glucose moiety from the C26 position. At the same time, the product ions at 579.3934 [M + H – H₂O – 2×162]⁺ and 417.3251 [M + H – H₂O – 3×162]⁺, which corresponded to skeleton residues by successive losses of terminal hexose, could also be clearly observed. Furthermore, the fragment
Table 2: HPLC/Q-TOF MS analysis for accurate mass measurements of constituents in 60% ethanol fraction.

| Number | $T_R$ (min) | Formula        | Selected ion | Theoretical mass ($m/z$) | Experimental mass ($m/z$) | Error (ppm) | Fragment ions in positive (+) ion mode | Identification                  |
|--------|-------------|----------------|--------------|--------------------------|---------------------------|-------------|---------------------------------------|----------------------------------|
| 1      | 29.8        | C$_{45}$H$_{76}$O$_{20}$ | [M + Na]$^+$ | 959.4822                 | 959.4833                  | −1.1        | 919, 757, 595, 433, 415, 271, 253     | Timosaponin N                   |
| 2      | 31.7        | C$_{45}$H$_{74}$O$_{19}$ | [M + Na]$^+$ | 941.4717                 | 941.4726                  | −1.0        | 901, 739, 577, 415, 273, 255          | Timosaponin M                   |
| 3      | 37.6        | C$_{45}$H$_{74}$O$_{19}$ | [M + Na]$^+$ | 943.4873                 | 943.4886                  | −1.4        | 903, 741, 579, 417, 273, 255          | Timosaponin BII                 |
| 4      | 38.5        | C$_{45}$H$_{74}$O$_{19}$ | [M + Na]$^+$ | 943.4873                 | 943.4882                  | −1.0        | 903, 741, 579, 417, 273, 255          | 25R-Timosaponin BII              |
| 5      | 39.2        | C$_{45}$H$_{74}$O$_{19}$ | [M + Na]$^+$ | 943.4873                 | 943.4871                  | 0.2         | 903, 741, 579, 417, 273, 255          | 25S-Officinalisnin-I             |
| 6      | 54.9        | C$_{6}$H$_{76}$O$_{18}$ | [M + Na]$^+$ | 925.4767                 | 925.4788                  | −2.3        | 741, 579, 417, 273, 255               | Timosaponin BII                 |
| 7      | 56.7        | C$_{59}$H$_{64}$O$_{14}$ | [M + Na]$^+$ | 779.4188                 | 779.4202                  | −1.8        | 739, 595, 433, 415, 273, 255          | Timosaponin G                   |
| 8      | 57.6        | C$_{39}$H$_{64}$O$_{14}$ | [M + Na]$^+$ | 781.4345                 | 781.4367                  | −2.8        | 741, 579, 417, 399, 271, 253          | Anemarrhena saponin I           |
| 9      | 58.0        | C$_{39}$H$_{64}$O$_{14}$ | [M + Na]$^+$ | 779.4188                 | 779.4189                  | −0.1        | 739, 579, 417, 273, 255               | Isomer of timosaponin G         |
| 10     | 58.6        | C$_{39}$H$_{64}$O$_{14}$ | [M + Na]$^+$ | 779.4188                 | 779.4184                  | 0.5         | 739, 595, 433, 415, 273, 253          | 25(27)-ene-Anemarrhena saponin I |
| 11     | 60.4        | C$_{39}$H$_{64}$O$_{14}$ | [M + Na]$^+$ | 779.4188                 | 779.4187                  | 0.1         | 757, 595, 433, 415, 271, 253          | Timosaponin A$_3$               |
| 12     | 62.2        | C$_{39}$H$_{64}$O$_{13}$ | [M + Na]$^+$ | 763.4239                 | 763.4237                  | 0.3         | 579, 417, 273, 255                    | Timosaponin AIV                 |
| 13     | 63.9        | C$_{39}$H$_{64}$O$_{13}$ | [M + Na]$^+$ | 763.4239                 | 763.4241                  | −0.3        | 579, 417, 273, 255                    | Timosaponin AIII                |
| 14     | 64.4        | C$_{39}$H$_{64}$O$_{13}$ | [M + Na]$^+$ | 763.4239                 | 763.4221                  | 2.4         | 579, 417, 273, 255                    | 25R-Timosaponin AIII            |
| 15     | 75.8        | C$_{31}$H$_{34}$O$_{4}$  | [M + Na]$^+$ | 601.3711                 | 601.3703                  | 1.3         | 417, 273, 255                         | Timosaponin A1                 |
ion at \( m/z \) 273.2139 \( [417.3251 - C_8H_{16}O_2]^+ \) was attributed to a skeleton residue by the cleavage of the C20–C22 and C17–C20 bonds due to the presence of a 16,22-epoxy residue and a 22,26-epoxy residue, and then the ion continued to lose \( \text{H}_2\text{O} \) to yield an ion at \( m/z \) 255.2030 \( [273.2139 - \text{H}_2\text{O}]^+ \). Major fragmentations proposed for timosaponin BII were presented in Figure 5.

Timosaponin BIII gave an \([M + H]^+\) ion at \( m/z \) 903.4941 and an \([M + Na]^+\) ion at \( m/z \) 925.4793, corresponding to an elemental composition \( C_{45}H_{74}O_{18} \). Its successive losses of one galactosyl and two glucosyls from the protonated ion led to the product ions at \( m/z \) 741.4482 \([M + H - 162]^+\), 579.3948 \([M + H - 2 \times 162]^+\), and 417.3240 \([M + H - 3 \times 162]^+\). In addition, the fragment ions found at \( m/z \) 273.2143 \( [417.3240 - C_8H_{16}O_2]^+ \) and 255.2040 \([273.2143 - \text{H}_2\text{O}]^+\) were originated from the consecutive elimination of the E-ring and \( \text{H}_2\text{O} \).

Timosaponin G produced a precursor ion \([M + Na]^+\) at \( m/z \) 779.4194. It showed a series of fragment ions at \( m/z \) 595.3933 \([M + H - 162]^+\), 433.3368 \([M + H - 2 \times 162]^+\), and 415.3244 \([M + H - \text{H}_2\text{O} - 2 \times 162]^+\), which could be attributed to losses of one glucosyl, one galactosyl, and \( \text{H}_2\text{O} \) from \([M + H]^+\) \( (m/z \) 757.4351). The fragment ions 273.2127 \( [415.3244 - C_8H_{14}O_2]^+ \) and 255.2000 \([273.2127 - \text{H}_2\text{O}]^+\) were produced by the consecutive elimination of the E-ring and \( \text{H}_2\text{O} \).

Anemarrhena saponin I yielded the sodic adduction \([M + Na]^+\) at \( m/z \) 781.4350, corresponding to its molecular formula

Figure 4: MS spectra of the authentic standards.
Evidence-Based Complementary and Alternative Medicine

![Diagram of the ESI-MS/MS fragmentation pathway of timosaponin BII.](image)

**Figure 5:** The proposed ESI-MS/MS fragmentation pathway of timosaponin BII.

![Diagram of the proposed structures of the fifteen compounds identified by Q-TOF-MS.](image)

**Figure 6:** The proposed structures of the fifteen compounds identified by Q-TOF-MS.

as C_{39}H_{66}O_{14}. The main fragment ions at m/z 741.4505 [M + H – H_2O]^+, 579.3817 [M + H – H_2O – 162]^+, 417.3410 [M + H – H_2O – 2 × 162]^+, and 399.2059 [M + H – 2 × H_2O – 2 × 162]^+ were produced directly from the parent ion, which could be attributed to losses of H_2O, one glucosyl, one galactosyl, and H_2O. Similarly, the fragment ions at m/z 271.1636 [417.3410 – C_8H_{18}O_2]^+ and 253.1493 [271.1636 – H_2O]^+ were also daughter ions produced from the parent ions by consecutive elimination of the E-ring and H_2O.

Timosaponin AIII displaying a series of fragment ions at m/z 741.4406 [M + H]^+. The characteristic fragment ions at m/z 273.2230 [417.3389 – C_8H_{16}O_2]^+ and 255.2105 [273.2230 – H_2O]^+ resulted from consecutive losses of E-ring and H_2O. Timosaponin AIV had the same formula and the similar fragmentation behavior as timosaponin AIII.

Based on the exact mass, authentic standards, fragment ions, retention time, and structures in the literature [15–24], the structures of the fifteen compounds (Figure 6) from the 60% ethanol fraction (Figure 7) were deduced as follows.

Peak 1 presented [M + Na]^+ ion with mass accuracy at m/z 959.4833. The molecular mass was 16 Da heavier than that of timosaponin BII. It produced fragment ions at m/z 919 [M + H – H_2O]^+, 757 [M + H – H_2O – 162]^+, 595 [M + H – H_2O – 2 × 162]^+, 433 [M + H – H_2O – 3 × 162]^+, and 415 [M + H – 2 × H_2O – 3 × 162]^+, which were attributed...
to the sequential losses of H$_2$O, one galactosyl, two glucosyls, and H$_2$O. Moreover, it was noteworthy that the fragment ions at $m/z$ 271 [415 – C$_8$H$_6$O$_2$]$^+$ and 253 [271 – H$_2$O]$^+$ originating from the consecutive elimination of the E-ring and H$_2$O were observed in the MS/MS spectrum. It was suggested that one more hydroxyl group substituent was at C2 position. Based on the fragment ions and retention time, it was tentatively identified as timosaponin N.

Peak 2, the major fragment ions at $m/z$ 901 [M + H – H$_2$O]$^+$, 739 [M + H – H$_2$O – 162]$^+$, 577 [M + H – H$_2$O – 2 × 162]$^+$, 415 [M + H – H$_2$O – 3 × 162]$^+$, 273 [415 – C$_8$H$_4$O$_2$]$^+$, and 255 [273 – H$_2$O]$^+$, could be attributed to losses of H$_2$O, three hexosyl residues, one formula C$_6$H$_{10}$O$_2$ and H$_2$O from the ion [M + Na]$^+$ ($m/z$ 941.4726). There was one double bond at the C25 and C27 positions [8]. Peak 2 was identified as timosaponin M.

Peak 3 was definitely identified as timosaponin BII in comparison with an authentic standard. The precursor ion [M + Na]$^+$ at $m/z$ 943.4886 was the base peak in ESi experiments. Peaks 4 and 5 showed the same formula and similar fragment ions as peak 3. Based on the chromatography behavior of steroidal saponin on a C$_{18}$ column, peak 4 was tentatively identified as the C25R stereoisomer of timosaponin BII. While peak 5 was identified as 25S-officialisin-I or its isomer [8].

Peak 6, peak 7, and peak 8 were identified as timosaponin BIll, timosaponin G, and *Anemarrhena* saponin I in comparison with authentic standards.

Peak 9 showed [M + Na]$^+$ ($m/z$ 779.4189) and [M + H – H$_2$O]$^+$ ($m/z$ 739.4244) ions. The fragment ions at $m/z$ 577 [M + H – H$_2$O – 162]$^+$, 415 [M + H – H$_2$O – 2 × 162]$^+$, 273 [415 – C$_8$H$_4$O$_2$]$^+$, and 255 [273 – H$_2$O]$^+$ were produced, corresponding to the neutral losses of one glucosyl, one galactosyl, E-ring, and H$_2$O. It was tentatively identified as isomer of timosaponin G.

Peak 10 presented [M + Na]$^+$ ion with mass accuracy at $m/z$ 779.4184. In addition to the dehydration product ion at $m/z$ 739 [M + H – H$_2$O]$^+$, a series of characteristic product ions at $m/z$ 595 [M + H – 162]$^+$, 433 [M + H – 2 × 162]$^+$, 415 [M + H – H$_2$O – 2 × 162]$^+$, 271 [415 – C$_8$H$_6$O$_2$]$^+$, and 253 [271 – H$_2$O]$^+$ were also observed. It was tentatively identified as 25(27)-(ene-) *Anemarrhena* saponin I.

Peak 11 was calculated as C$_{33}$H$_{55}$O$_{13}$ based on the accurate mass measurement [M + Na]$^+$ ($m/z$ 779.4187). The ions at $m/z$ 757 [M + H]$^+$, 595 [M + H – 162]$^+$, 433 [M + H – 2 × 162]$^+$, 415 [M + H – H$_2$O – 2 × 162]$^+$, 271 [415 – C$_8$H$_6$O$_2$]$^+$, and 253 [271 – H$_2$O]$^+$ indicated one hydroxyl group substituent of the aglycone. It was tentatively identified as timosaponin A$_2$.

Peaks 12 and 13 were identified as timosaponin AIV and timosaponin AIII by authentic standards. Peak 14 yielded the sodic adduct ion [M + Na]$^+$ at $m/z$ 763.4237. It displayed a series of fragment ions at $m/z$ 579 [M + H – 162]$^+$, 417 [M + H – 2 × 162]$^+$, 273 [417 – C$_8$H$_6$O$_2$]$^+$, and 255 [273 – H$_2$O]$^+$.

Peaks 15 showed the [M + H]$^+$ ion at $m/z$ 579.3892 (C$_{33}$H$_{55}$O$_{8,9}$), 162 Da less than that of timosaponin AIII. The product ions such as $m/z$ 417 [M + H – 162]$^+$, 399 [M + H – H$_2$O – 162]$^+$, 273 [417 – C$_8$H$_6$O$_2$]$^+$, and 255 [273 – H$_2$O]$^+$ could be found in their MS/MS spectrum. From this, peak 15 was identified as timosaponin A-I.

3.4. Isolation and Purification of Compounds from *Anemarrhena asphodeloides* Bge. Twenty-five compounds were obtained after repeated isolation and purification. On the basis of spectroscopic analysis (MS, $^1$H NMR, $^{13}$C NMR, DEPT135, HSQC, HMBC, and NOESY spectra) and in comparison with the previously reported spectral data [25–34], the structures of these compounds were shown in Figure 8. All the isolates were subjected to the cholinesterase inhibitory activity assay (Table 3).

4. Discussion

The anticholinesterase activity of the agents was tested in the presence of a known concentration. It was one of the approaches to study the effect of treating Alzheimer’s disease. The anticholinesterase inhibition ratio of the agents was expressed as percentage inhibition ratio based on the optical density. The conditions of AChE and BuChE inhibitory assay were carried out by a series of literature reports and experiments.

To determine which fraction has anticholinesterase activity, the rhizome of *Anemarrhena asphodeloides* was fractionated further by a series of extractions with different solvents and techniques. The findings revealed that more bioactive components would be extracted by dichloromethane, ethyl acetate, and acetone. The extracts dealt with by the ultrasonic and cold soak method had higher inhibition ratio than the extracts dealt with by the heat reflux method. It is proposed that the molecular structures of the active constituents may be destroyed at a high temperature.
The effect of ethyl acetate extract extracted by the ultrasonic method on inhibiting activity of cholinesterase was better than those dealt with by other solvents and methods. The ethyl acetate crude extract of *Anemarrhena asphodeloides* may also contain many compounds with differing polarities, so it was fractionated further by a D-101 macroporous resin column. The bioactive compounds of the 60% ethanol fraction were analyzed by HPLC-QTOF-MS system. The type of compounds in the 60% ethanol fraction could be deduced by the MS data. If the ions [M + Na]⁺ and [M + H - H₂O]⁺ were detected and the [M+H]⁺ ion was not observed, the saponin would be a furostanol saponin with the C22 hydroxyl group. If the ions at \( m/z \) 417, 255, and 273 were detected, there should be no substituent attached to the sarsasaponin. If the ions at \( m/z \) 433 and 415 were observed, there should be one more hydroxyl group substituent on the aglycone. The retention time of saponins would be affected by the number, classes, and connection orders of sugar moieties and the number and position of hydroxyl group substituent at the aglycone. What is more, the retention time of steroidal saponins with the 25R configuration was longer than those with the 25S configuration on a C18 column.

Twenty-five compounds were isolated from the active fraction. The structure-activity relationships were discussed based on the results of cholinesterase inhibitory activity. It showed that the compounds with the C₆–C₃–C₆ skeleton probably had both AChE and BuChE inhibitory activities. Compound 3 showed potential BuChE inhibitory activity with the inhibition ratio of 75.8%. Xanthone and benzene derivatives exhibited no or little activity. Lignans showed weak BuChE inhibitory activity. The steroidal saponins had moderate or weak AChE inhibitory activity. It was supposed that adding OH groups to the steroidal saponins may increase the effect a little. Although some of the individual compounds exhibited potential *in vitro* activity, they were less effective than the 60% ethanol fraction and this might be due to a synergistic action among the active components or maybe the most active constituents have not been isolated by us.

Steroid saponins were considered as potentially drug preventing and treating neurodegenerative diseases, such as Alzheimer's disease. However, we found that compounds with the C₆–C₃–C₆ skeleton probably had both AChE and BuChE inhibitory activities, especially compound 3. The activity *in vivo* needs to be tested in the future.

5. Conclusion

AChE and BuChE inhibitory activities of *Anemarrhena asphodeloides* Bge extracted with three different techniques
Table 3: The effects of the twenty-five compounds on AChE and BuChE inhibitory activities.

| Compounds | AChE inhibition (%) | BuChE inhibition (%) |
|-----------|---------------------|----------------------|
| 1         | 17.9 ± 0.3          | 37.6 ± 0.6           |
| 2         | 15.2 ± 0.2          | 28.1 ± 0.4           |
| 3         | 12.5 ± 0.4          | 75.8 ± 0.7           |
| 4         | —                   | —                    |
| 5         | 14.1 ± 0.3          | 35.3 ± 0.5           |
| 6         | 17.9 ± 0.2          | 36.0 ± 0.4           |
| 7         | 14.2 ± 0.5          | 0.6 ± 0.1            |
| 8         | —                   | —                    |
| 9         | —                   | —                    |
| 10        | 0.9 ± 0.1           | 0.1 ± 0.1            |
| 11        | 7.9 ± 0.3           | 4.0 ± 0.2            |
| 12        | 1.7 ± 0.2           | 15.1 ± 0.3           |
| 13        | 18.5 ± 0.4          | 0.5 ± 0.1            |
| 14        | 27.2 ± 0.2          | 4.2 ± 0.2            |
| 15        | 21.6 ± 0.4          | —                    |
| 16        | 11 ± 0.1            | —                    |
| 17        | 13.2 ± 0.3          | —                    |
| 18        | 15.9 ± 0.4          | —                    |
| 19        | 23.5 ± 0.4          | 12.3 ± 0.6           |
| 20        | 18.4 ± 0.4          | —                    |
| 21        | 19.2 ± 0.3          | —                    |
| 22        | 17.3 ± 0.3          | —                    |
| 23        | 20.3 ± 0.5          | 7.3 ± 0.2            |
| 24        | 21.1 ± 0.6          | —                    |
| 25        | 22.4 ± 0.2          | 2.8 ± 0.2            |
| Donepezil | 98.2 ± 0.8          | 79.8 ± 0.7           |

and ten kinds of solvents were studied. Anemarrhena asphodeloides Bge extracted with ethyl acetate by the ultrasonic technique had the most potential anticholinesterase activity. The extract was partitioned into six fractions after applying to a D-101 macroporous resin column, and active compounds were concentrated into 60% ethanol fraction. Fifteen main peaks of this fraction were identified and tentatively characterized based on the HPLC-QTOF-MS technique, standards, and literature reports. Twenty-five compounds were obtained from 60% ethanol fraction after repeated isolation and purification. The structure-activity relationships were discussed based on the results of cholinesterase inhibitory activity.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

The authors are grateful to financial supports from Natural Science Foundation of China (81373925), “Liaoning Bai Qian Wan Talents Program” (2011921044), Social Development Project of Liaoning Science and Technology Committee (201404012-3), Liaoning Province Doctoral Scientific Research Start-up Funds (20111139), Project of Shenyang Science and Technology Bureau (F12-161-9-00), Program for Innovative Research Team of the Ministry of Education, and Program for Liaoning Innovative Research Team in University.

**References**

[1] M. Goedert and M. G. Spillantini, "A century of Alzheimer's disease," Science, vol. 314, no. 5800, pp. 777–781, 2006.
[2] J. S. da Costa, J. P. B. Lopes, D. Russowsky et al., "Synthesis of tarcine-lopheine hybrids via one-pot four component reaction and biological evaluation as acetyl- and butyrylcholinesterase inhibitors," European Journal of Medicinal Chemistry, vol. 62, pp. 556–563, 2013.
[3] H. Q. Lin, M. T. Ho, L. S. Lau, K. K. Wong, P. C. Shaw, and D. C. C. Wan, "Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease," Chemico-Biological Interactions, vol. 175, no. 1–3, pp. 352–354, 2008.
[4] E. Perry, J. Court, R. Goodchild et al., "Clinical neurochemistry: developments in dementia research based on brain bank material," Journal of Neural Transmission, vol. 105, no. 8–9, pp. 915–933, 1998.
[5] R. T. Delfino, T. S. Ribeiro, and J. D. figueroa-Villar, "Organo-phosphorus compounds as chemical warfare agents: a review," Journal of the Brazilian Chemical Society, vol. 20, no. 3, pp. 407–428, 2009.
[6] E. K. Perry, R. H. Perry, G. Blessed, and B. E. Tomlinson, "Changes in brain cholinesterases in senile dementia of Alzheimer type," Neuropathology and Applied Neurobiology, vol. 4, no. 4, pp. 273–277, 1978.
[7] N. Wszelaki, A. Kuciun, and A. Kiss, "Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity," Acta Pharmaceutica, vol. 60, no. 1, pp. 119–128, 2010.
[8] Y. Zhao, L. P. Kang, H. S. Yu et al., "Structure characterization and identification of steroidal saponins from the rhizomes of Anemarrhena asphodeloides by ultra performance liquid-chromatography and hybrid quadrupole time-of-flight mass spectrometry," International Journal of Mass Spectrometry, vol. 7, no. 17, pp. 341–342, 2013.
[9] B. Lee, K. Jung, and D.-H. Kim, "Timosaponin AIII, a saponin isolated from Anemarrhena asphodeloides, ameliorates learning and memory deficits in mice," Pharmacology Biochemistry and Behavior, vol. 93, no. 2, pp. 121–127, 2009.
[10] Z. X. Peng, Y. Wang, X. Gu, Y. Y. Wen, and C. Yan, "A platform for fast screening potential anti-breast cancer compounds in traditional Chinese medicines," Biomedical Chromatography, vol. 27, no. 12, pp. 1759–1766, 2013.
[11] X. Zhang, L.-W. Qi, L. Yi, P. Li, X.-D. Wen, and Q.-T. Yu, "Screening and identification of potential bioactive components in a combined prescription of Danggui Buxue decoction using cell extraction coupled with high performance liquid chromatography," Biomedical Chromatography, vol. 22, no. 2, pp. 157–163, 2008.
[12] Y. Hou, X. Cao, L. Dong et al., "Bioactivity-based liquid chromatography-coupled electrospray ionization tandem ion trap/time of flight mass spectrometry for β2AR agonist identification in alkaloidal extract of Alstonia scholaris," Journal of Chromatography A, vol. 1227, pp. 203–209, 2012.
[13] Z.-H. Su, G.-A. Zou, A. Preiss, H.-W. Zhang, and Z.-M. Zou, "Online identification of the antioxidant constituents of traditional Chinese medicine formula Chaihu-Shu-Gan-San by LC-LTQ-Orbitrap mass spectrometry and microplate spectrophotometry," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 53, no. 3, pp. 454–461, 2010.

[14] G. L. Ellman, K. D. Courtney, V. Andres Jr., and R. M. Featherstone, "A new and rapid colorimetric determination of acetylcholinesterase activity," *Biochemical Pharmacology*, vol. 7, no. 2, pp. 88–95, 1961.

[15] J. Zhang, B. P. Ma, L. P. Kang et al., "Furostanol saponins from the fresh rhizomes of Polygonatum kingianum," *Chemical and Pharmaceutical Bulletin*, vol. 54, no. 7, pp. 931–935, 2006.

[16] J. Zhu, X. Guo, S. Fu, X. Zhang, and X. Liang, "Characterization of steroidal saponins in crude extracts from Dioscorea zingiberensis C. H. Wright by ultra-performance liquid chromatography/electrospray ionization quadrupole time-of-flight tandem mass spectrometry," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 53, no. 3, pp. 462–474, 2010.

[17] L. P. Kang, J. Zhang, Y. Cong et al., "Steroidal glycosides from the rhizomes of *Anemarrhena asphodeloides* and their antiplatelet aggregation activity," *Planta Medica*, vol. 78, no. 6, pp. 611–616, 2012.

[18] L. P. Kang, K. Yu, Y. Zhao et al., "Characterization of steroidal glycosides from the extract of Paris Polyphylla var. Yunnanensis by UPLC/Q-TOF MSE," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 62, no. 6, pp. 235–249, 2012.

[19] L. P. Kang, Y. Zhao, X. Pang et al., "Characterization and identification of steroidal saponins from the seeds of Trigonella foenum-graecum by ultra-high-performance liquid chromatography and hybrid time-of-flight mass spectrometry," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 74, no. 23, pp. 257–267, 2013.

[20] R. Li, Y. Zhou, Z. Wu, and L. Ding, "ESI-QqTOF-MS/MS and APCI-IT-MS/MS analysis of steroid saponins from the rhizomes of Dioscorea panthaica," *Journal of Mass Spectrometry*, vol. 41, no. 1, pp. 1–22, 2006.

[21] J. Y. Ui, S. L. Ye, J. Hana et al., "Identification of antiadipogenic constituents of the rhizomes of *Anemarrhena asphodeloides*," *Journal of Natural Products*, vol. 72, no. 10, pp. 1895–1898, 2009.

[22] X. Ji and Y. F. Feng, "Advances in studies on saponins in *Anemarrhena asphodeloides*", *Chinese Traditional and Herbal Drugs*, vol. 41, no. 4, pp. 12–15, 2010.

[23] X. Pang, L. P. Kang, H. S. Yu et al., "Rapid isolation of new furostanol saponins from fenugreek seeds based on ultra-performance liquid chromatography coupled with a hybrid quadrupole time-of-flight tandem mass spectrometry," *Journal of Separation Science*, vol. 35, no. 12, pp. 1538–1550, 2012.

[24] Y. J. Kang, H. J. Chung, J. W. Nam et al., "Cytotoxic and antineoplastic activity of timosaponin A-III for human colon cancer cells," *Journal of Natural Products*, vol. 74, no. 4, pp. 701–706, 2011.

[25] M. Takahashi, C. Konno, and H. Hikino, "Isolation and hypoglycemic activity of anemarans A, B, C and D, glycos of *Anemarrhena asphodeloides* rhizomes," *Planta Medica*, vol. 2, pp. 100–102, 1985.

[26] B. N. Su, Q. X. Zhu, and Z. J. Jia, "Nor-lignan and sesquiterpenes from *Cremanthodium ellissii*," *Phytochemistry*, vol. 53, no. 8, pp. 1103–1108, 2000.

[27] W. F. Tinto, J. L. Simmons-Boyce, S. McLean, and W. F. Reynolds, "Constituents of *Agave americana* and *Agave barbadensis*," *Fitoterapia*, vol. 76, no. 6, pp. 594–597, 2005.

[28] W. Y. Tsui and G. D. Brown, "(+)-Nyasol from *Asparagus cochinensis*," *Phytochemistry*, vol. 43, no. 6, pp. 1413–1415, 1996.

[29] S. Tsukamoto, T. Wakana, K. Koimaru, T. Yoshida, M. Sato, and T. Ohta, "7-Hydroxy-3-(4-hydroxybenzyl)chroman and Broussonin B: neurotrophic compounds, isolated from *Anemarrhena asphodeloides* BUNGE, function as proteasome inhibitors," *Biological and Pharmaceutical Bulletin*, vol. 28, no. 9, pp. 1798–1800, 2005.

[30] J. Zhang, Z. Meng, M. Zhang, D. Ma, S. Xu, and H. Kodama, "Effect of six steroid saponins isolated from *Anemarrhena rhizoma* on platelet aggregation and hemolysis in human blood," *Clinica Chimica Acta*, vol. 289, no. 1-2, pp. 79–88, 1999.

[31] Q. Sun, A. Sun, and R. Liu, "Preparative isolation and purification of four compounds from the Chinese medicinal herb *Rhizoma Anemarrhenae* by high-speed counter-current chromatography," *Journal of Chromatography A*, vol. 1104, no. 1-2, pp. 69–74, 2006.

[32] Z. Y. Meng, J. Y. Zhang, S. X. Xu, and K. Sugahara, "Steroidal saponins from *Anemarrhena asphodeloides* and their effects on superoxide generation," *Planta Medica*, vol. 65, no. 7, pp. 661–663, 1999.

[33] U. J. Youn, J.-E. Jang, J.-W. Nam et al., "Anti-respiratory syncytial virus (RSV) activity of timosaponin A-III from the rhizomes of *Anemarrhena asphodeloides*," *Journal of Medicinal Plant Research*, vol. 5, no. 7, pp. 1062–1065, 2011.

[34] B. Shao, H. Guo, Y. Cui, M. Ye, J. Han, and D. Guo, "Steroidal saponins from smilax China and their anti-inflammatory activities," *Phytochemistry*, vol. 68, no. 5, pp. 623–630, 2007.